Cancers, Volume 15, Issue 2
2023 January-2 - 233 articles
Cover Story: Carboxypeptidase type II, also known as prostate-specific membrane antigen (PSMA), is expressed on the surface of neovascular endothelial cells in various solid tumors, including clear cell renal cancer (ccRCC). Based on its genetic characteristics, it is considered a highly vascularized tumor, which might be a rationale for using PET/CT imaging with PSMA-targeting rather than [18F]F-FDG, which is not routinely recommended due to its excretion pathway and its low accuracy. In the studies included in this systematic review, PSMA-targeted PET/CT showed promising results in the diagnostics of ccRCC, being able to detect more lesions than conventional imaging examinations. It can identify ccRCC lesions with a more aggressive phenotype, predict treatment outcomes and change patient management in a significant percentage of patients. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.